title: Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma.
abstract: OBJECTIVE
  While both efficacy and safety of anti-PD-1 agents seem to be independent of previous treatment with anti-CTLA-4, limited data exist of efficacy and toxicity of ipilimumab after progression on anti-PD-1 therapy. This retrospective analysis describes the efficacy and safety of sequential therapy with ipilimumab in patients with metastatic melanoma who progressed on anti-PD-1 antibody.
  
  
  METHODS
  Nine patients who progressed on anti-PD-1 therapy received four cycles of ipilimumab 3 mg/kg every 3 weeks.
  
  
  RESULTS
  Two out of nine patients (2/9; 22.2%) showed a partial response, and seven patients (7/9; 77.8%) experienced disease progression. Median progression-free survival was 3.14 months (95% CI: 2.56-3.71), and the median overall survival since the start of anti-PD-1 therapy was 16.8 months (95% CI: 8.1-25.4). Five (5/9; 55.6%) patients experienced grade 3 immune-related adverse events. No grade 4 or 5 adverse events were reported.
  
  
  CONCLUSIONS
  In this small retrospective series of cases, the efficacy of ipilimumab post-anti-PD-1 was similar to that described in the previous reports on ipilimumab.
authors: Medical Oncology Department, Hospital Clinic Barcelona, Villaroel 170, 08036 Barcelona, Spain.|Targeted Therapeutics & Translational Genomics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona, Spain.
authors: Francisco
authors: F
authors: Aya
authors: Medical Oncology Department, Hospital Clinic Barcelona, Villaroel 170, 08036 Barcelona, Spain.|Targeted Therapeutics & Translational Genomics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona, Spain.
authors: Lydia
authors: L
authors: Gaba
authors: Medical Oncology Department, Hospital Clinic Barcelona, Villaroel 170, 08036 Barcelona, Spain.|Targeted Therapeutics & Translational Genomics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona, Spain.
authors: Iván
authors: I
authors: Victoria
authors: Medical Oncology Department, Hospital Clinic Barcelona, Villaroel 170, 08036 Barcelona, Spain.|Targeted Therapeutics & Translational Genomics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona, Spain.
authors: Aranzazu
authors: A
authors: Fernández-Martínez
authors: Medical Oncology Department, Hospital Clinic Barcelona, Villaroel 170, 08036 Barcelona, Spain.|Targeted Therapeutics & Translational Genomics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona, Spain.
authors: Mónica
authors: M
authors: Tosca
authors: Medical Oncology Department, Hospital Clinic Barcelona, Villaroel 170, 08036 Barcelona, Spain.|Targeted Therapeutics & Translational Genomics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona, Spain.
authors: Aleix
authors: A
authors: Prat
authors: Medical Oncology Department, Hospital Clinic Barcelona, Villaroel 170, 08036 Barcelona, Spain.|Targeted Therapeutics & Translational Genomics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona, Spain.
authors: Ana
authors: A
authors: Arance
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors*; D018450:Disease Progression; D005260:Female; D006801:Humans; D000074324:Ipilimumab; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology*; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors; D019233:Retreatment; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D060908:CTLA-4 Antigen; D000074324:Ipilimumab; D061026:Programmed Cell Death 1 Receptor
keywords: advanced melanoma; anti-PD-1; immune-related adverse event; ipilimumab; sequence of immunotherapies